CERo Therapeutics Completes IND-Enabling Activities, Following Fruitful Lead Compound CER-1236 Manufacturing Runs

June 13, 2024

DENVER, Colo., Jun 13, 2024 (247marketnews.com)- CERo Therapeutics Holdings, Inc. (Nasdaq:CERO) successfully completed multiple manufacturing runs, required to meet safety and efficacy standards for drug administration in clinical trials, and the final technical activity requirement for the Company prior to complete its Investigational New Drug Application (IND) package.

Brian Atwood, CERo’s Chairman and CEO, stated, “This is an important milestone for CERo, paving the way for us to complete our IND package for review by the FDA, which is the final step prior to beginning clinical trials in humans. We are grateful for the hard work from our entire team as we reach this important milestone and look forward to providing updates soon regarding the outcome of the filing.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (CERO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.